Why Is Anteris Technologies (ASX: AVR) in the FMP Top 30 Momentum List?

Written by Christopher Hall, AdvDipFP | Authorised Representative, AFSL 526688 | July 2026

Analysis sourced from Gary Glover (AR 259215), Authorised Representative, Novus Capital Limited (AFSL 238 168)

Anteris Technologies Ltd (ASX: AVR) is an Australian structural-heart medical-device company. It sits at rank #27 on the Finer Market Points Top 30 momentum list for the week ending 3 July 2026, up 88.42% over the quarter (quarterly rank #22) and 64.73% since its FMP Launch Pad entry 42 days earlier — strength that held even though the stock eased 6.87% on the week.

What Is Driving the Anteris Technologies Share Price?

A momentum-list appearance measures recent price performance, not a company's fundamentals. In the 3 July 2026 recorded session, Gary Glover (AR 259215), Authorised Representative of Novus Capital Limited (AFSL 238 168), who reviews ASX momentum stocks in a recorded weekly session with Finer Market Points, walked through the technical structure: a cup formation with a tight handle, no meaningful selling on the pullback, and then a break of a prior swing high that pushed the stock above its 50-day moving average on very low volume — a Wyckoff-style anomaly, because a genuine breakout on almost no supply signals little resistance overhead.

Gary's anecdotal observation was that the setup met his criteria for a trade. The obstacle was practical rather than technical: neither Gary nor Christopher Hall judged there to be enough market depth in the stock to build a position at meaningful size. That constraint — a strong chart that cannot be traded at scale — is a recurring theme Gary has flagged before:

Gary Glover's anecdotal observation is that many technically sound small-cap patterns have insufficient market depth to trade at meaningful size — adequate liquidity is a hard requirement that cannot be overridden by a strong technical signal.

For Anteris, the 88.42% quarterly move and 42 days of persistence on the FMP Launch Pad describe sustained relative strength, while the thin-liquidity caveat explains why a professional trader might admire the chart yet stay on the sidelines. Remember that past performance is no guarantee of future results, and all trading involves risk.

Key Metrics at Time of Coverage

Metric	Value
Rank (FMP Top 30 momentum, week ending 3 July 2026)	#27 of 30
Momentum score	0.1846
Weekly gain	-6.87% (weekly rank #492)
Quarterly gain	+88.42% (quarterly rank #22)
Days on FMP Top 30 list	31
Launch Pad entry	42 days ago
Gain since Launch Pad Top 10	+64.73%
Sector (plain English)	Structural-heart medical devices
Data source	FMP Momentum Research, week ending 3 July 2026

Frequently Asked Questions

Why has Anteris Technologies' share price gone up so much?

Anteris Technologies (ASX: AVR) gained 88.42% over the quarter to the week ending 3 July 2026 and ranks #27 on the FMP Top 30 momentum list, up 64.73% since its Launch Pad entry 42 days earlier. The advance reflects sustained relative strength across the quarter; the stock eased 6.87% in the final week. Past performance is no guarantee of future results.

What does Anteris Technologies do?

Anteris Technologies Ltd (ASX: AVR) is a structural-heart medical-device company. Its lead technology is the DurAVR transcatheter heart valve, developed to treat aortic stenosis using the company's ADAPT tissue-processing platform. The company was formerly named Admedus Limited.

Does Anteris Technologies sell a commercial heart valve yet?

Anteris is a development-stage medical-device company: its DurAVR heart valve is in clinical development rather than broad commercial sale. A momentum-list appearance reflects share-price performance, not regulatory approval or revenue.

Is AVR the same company as Admedus?

Yes. Anteris Technologies Ltd was formerly named Admedus Limited. Investors who followed the Admedus story track the same company under the ticker AVR.

Is Anteris Technologies a good stock to buy?

This note does not make that judgement. A momentum-list appearance measures recent price momentum, not company quality or investment merit — and Gary Glover specifically noted the stock's thin liquidity as a practical barrier to trading it at size. This content is general educational information, not a recommendation.

Access the Data

FMP members access the weekly Top 30 ASX momentum data — the same proprietary research that flagged Anteris Technologies — 19 hours before the Gary Glover weekly session goes live. For information on FMP YouTube Momentum Profile membership, visit the membership page.

Sources

#	Source	Type
1	FMP Momentum Research — weekly Top 30 momentum data, week ending 3 July 2026	FMP Proprietary Data
2	Gary Glover chart commentary, recorded FMP market analysis session, 3 July 2026	FMP Session
3	Gary Glover practitioner observation (small-cap liquidity as a hard requirement), recorded FMP session, 15 May 2026, via FMP insights repository	FMP Session
4	Anteris Technologies Ltd — company profile (business description; former name Admedus Limited)	Company Profile

Gary Glover's contributions are anecdotal observations drawn from his trading career, summarised by Finer Market Points for educational purposes.

This article is based on analysis and commentary provided by Gary Glover (AR 259215), Authorised Representative of Novus Capital Limited (AFSL 238 168), during a recorded market analysis session on 3 July 2026. Content has been edited and summarised by Finer Market Points for educational purposes. Gary Glover has not independently reviewed or endorsed this publication.

Educational Disclaimer: This content is for educational purposes only and does not constitute financial advice. Past performance is no guarantee of future results. Consider your financial situation and seek professional advice before making investment decisions.

Finer Market Points Pty Ltd, CAR 1304002, AFSL 526688, ABN 87 645 284 680. This general information is educational only and not financial advice, recommendation, forecast or solicitation. Consider your objectives, financial situation and needs before acting. Seek appropriate professional advice. We accept no liability for any loss or damages arising from use. Authors and presenters may hold positions in discussed companies and investment products.